Nuvectis Pharma prices $100M public offering of 5M shares at $20.00 per share

Nuvectis Pharma, Inc.

Priced underwritten public offering of 5,000,000 shares at $20.00 per share for gross proceeds of $100 million.
Net proceeds expected ~$93 million (or ~$107 million if underwriters' 30-day option for 750,000 additional shares is exercised).
Offering expected to close on July 1, 2026; Cantor Fitzgerald acting as sole book-runner.
Proceeds to fund development of NXP100, NXP200, NXP900 and for general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.